The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)

Samsung Medical Center1 site in 1 country1,200 target enrollmentSeptember 2006

ConditionsCoronary Artery Disease

InterventionsAspirin, Clopidogrel

DrugsAspirin, Clopidogrel

Overview

Phase: Not Applicable
Intervention: Aspirin, Clopidogrel
Conditions: Coronary Artery Disease
Sponsor: Samsung Medical Center
Enrollment: 1200
Locations: 1
Primary Endpoint: Incidence of definite stent thrombosis by Academic Research Consortium Proposed Standard
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.

Registry

clinicaltrials.gov

Start Date

September 2006

End Date

April 2009

Last Updated

14 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

•Patients with clinically significant de novo coronary artery disease
•Stenting only with Endeavor® stents
•The sum of stent length is less than 60 mm for one lesion. The sum of stent length in multiple lesions does not matter.

Exclusion Criteria

•Cardiogenic shock
•ST-elevation myocardial infarction within 48 hours of symptom onset
•Prior implantation of drug-eluting stents
•Left ventricular dysfunction (echocardiographic left ventricular ejection fraction \< 25%)
•Stenting both branch of bifurcation lesion
•Left main trunk lesion
•Graft vessels
•Patients who have to receive clopidogrel due to other conditions
•Patients who have to receive warfarin, cilostazol or other antiplatelet therapy
•Patient with chronic renal failure (S-Cr \> 2.0 mg/dl)